CASIA OpenIR  > 中国科学院分子影像重点实验室
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Song, Jiangdian1,2,3; Shi, Jingyun4; Dong, Di1,5; Fang, Mengjie1,5; Zhong, Wenzhao6; Wang, Kun1,5; Wu, Ning7,8; Huang, Yanqi9; Liu, Zhenyu1,5; Cheng, Yue10; Gan, Yuncui10; Zhou, Yongzhao10; Zhou, Ping10; Chen, Bojiang10; Liang, Changhong9; Liu, Zaiyi9; Li, Weimin10; Tian, Jie1,5,11
Source PublicationCLINICAL CANCER RESEARCH
2018-08-01
Volume24Issue:15Pages:3583-3592
SubtypeArticle
AbstractPurpose: We established a CT-derived approach to achieve accurate progression-free survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter, stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients.
WOS HeadingsScience & Technology ; Life Sciences & Biomedicine
DOI10.1158/1078-0432.CCR-17-2507
WOS KeywordCELL LUNG-CANCER ; TYROSINE KINASE INHIBITORS ; OPEN-LABEL ; ACQUIRED-RESISTANCE ; PHASE-III ; 1ST-LINE ERLOTINIB ; MUTATIONS ; CHEMOTHERAPY ; TRIAL ; MULTICENTER
Indexed BySCI
Language英语
Funding OrganizationNatural Science Foundation of China(81771924 ; National Key R&D Program of China(2017YFA0205200 ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences(KFJ-SW-STS-160) ; Instrument Developing Project of the Chinese Academy of Sciences(YZ201502) ; Beijing Municipal Science and Technology Commission(Z171100000117023 ; Youth Innovation Promotion Association CAS ; 81501616 ; 2017YFC1308700 ; Z161100002616022) ; 61671449 ; 2017YFC1308701 ; 61231004 ; 2017YFC1309100) ; 81671854 ; 81501549)
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000440600200014
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/21847
Collection中国科学院分子影像重点实验室
Affiliation1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China
2.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China
3.Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China
4.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China
5.Univ Chinese Acad Sci, Beijing, Peoples R China
6.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
7.Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, PET CT Ctr, Beijing, Peoples R China
8.Peking Union Med Coll, Beijing, Peoples R China
9.Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Radiol, Guangzhou, Guangdong, Peoples R China
10.West China Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China
11.Beijing Key Lab Mol Imaging, Beijing, Peoples R China
Recommended Citation
GB/T 7714
Song, Jiangdian,Shi, Jingyun,Dong, Di,et al. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy[J]. CLINICAL CANCER RESEARCH,2018,24(15):3583-3592.
APA Song, Jiangdian.,Shi, Jingyun.,Dong, Di.,Fang, Mengjie.,Zhong, Wenzhao.,...&Tian, Jie.(2018).A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.CLINICAL CANCER RESEARCH,24(15),3583-3592.
MLA Song, Jiangdian,et al."A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy".CLINICAL CANCER RESEARCH 24.15(2018):3583-3592.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Song, Jiangdian]'s Articles
[Shi, Jingyun]'s Articles
[Dong, Di]'s Articles
Baidu academic
Similar articles in Baidu academic
[Song, Jiangdian]'s Articles
[Shi, Jingyun]'s Articles
[Dong, Di]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Song, Jiangdian]'s Articles
[Shi, Jingyun]'s Articles
[Dong, Di]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.